| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
1,518,000 |
| Market
Cap: |
9.56(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$5.2 - $18.63 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Kala Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of therapies for diseases of the eye. Co.'s two marketed products are EYSUVIS® (loteprednol etabonate ophthalmic suspension) 0.25%, for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease, and INVELTYS® (loteprednol etabonate ophthalmic suspension) 1%, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Co. is also progressing its pipeline of proprietary programs targeted to address front and back of the eye diseases, including KPI-287 and glucocorticoid receptor modulators.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
11,400 |
11,400 |
3,865,837 |
| Total Sell Value |
$0 |
$76,777 |
$76,777 |
$1,938,481 |
| Total People Sold |
0 |
6 |
6 |
7 |
| Total Sell Transactions |
0 |
6 |
6 |
15 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Reumuth Mary |
CHIEF FINANCIAL OFFICER |
• – – |
2024-01-04 |
4 |
AS |
$6.74 |
$8,270 |
D/D |
(1,227) |
66,136 |
|
-10% |
|
| Reumuth Mary |
CHIEF FINANCIAL OFFICER |
• – – |
2024-01-04 |
4 |
A |
$0.00 |
$0 |
D/D |
4,600 |
67,363 |
|
- |
|
| Kharabi Darius |
CHIEF BUSINESS OFFICER |
• – – |
2024-01-04 |
4 |
AS |
$6.73 |
$9,321 |
D/D |
(1,385) |
65,117 |
|
-10% |
|
| Kharabi Darius |
CHIEF BUSINESS OFFICER |
• – – |
2024-01-04 |
4 |
A |
$0.00 |
$0 |
D/D |
4,600 |
66,502 |
|
- |
|
| Iwicki Mark T |
CHIEF EXECUTIVE OFFICER |
• • – |
2024-01-04 |
4 |
AS |
$6.73 |
$30,547 |
D/D |
(4,539) |
286,315 |
|
-10% |
|
| Iwicki Mark T |
CHIEF EXECUTIVE OFFICER |
• • – |
2024-01-04 |
4 |
A |
$0.00 |
$0 |
D/D |
14,300 |
290,854 |
|
- |
|
| Bazemore Todd |
SEE REMARKS |
• – – |
2024-01-04 |
4 |
AS |
$6.74 |
$9,470 |
D/D |
(1,405) |
0 |
|
-10% |
|
| Bazemore Todd |
SEE REMARKS |
• – – |
2024-01-04 |
4 |
A |
$0.00 |
$0 |
D/D |
6,500 |
0 |
|
- |
|
| Trachtenberg Eric |
SEE REMARKS |
• – – |
2024-01-04 |
4 |
AS |
$6.74 |
$8,270 |
D/D |
(1,227) |
68,066 |
|
-10% |
|
| Trachtenberg Eric |
SEE REMARKS |
• – – |
2024-01-04 |
4 |
A |
$0.00 |
$0 |
D/D |
4,600 |
69,293 |
|
- |
|
| Brazzell Kim |
SEE REMARKS |
• – – |
2024-01-04 |
4 |
AS |
$6.74 |
$10,899 |
D/D |
(1,617) |
91,473 |
|
-10% |
|
| Brazzell Kim |
SEE REMARKS |
• – – |
2024-01-04 |
4 |
A |
$0.00 |
$0 |
D/D |
6,500 |
93,090 |
|
- |
|
| Kharabi Darius |
CHIEF BUSINESS OFFICER |
• – – |
2023-06-22 |
4 |
A |
$0.00 |
$0 |
D/D |
36,847 |
61,902 |
|
- |
|
| Koven Andrew I |
|
– • – |
2023-06-22 |
4 |
A |
$0.00 |
$0 |
D/D |
8,915 |
12,172 |
|
- |
|
| Perry Gregory D |
|
– • – |
2023-06-22 |
4 |
A |
$0.00 |
$0 |
D/D |
6,956 |
9,494 |
|
- |
|
| Reumuth Mary |
CHIEF FINANCIAL OFFICER |
• – – |
2023-06-22 |
4 |
A |
$0.00 |
$0 |
D/D |
36,144 |
62,763 |
|
- |
|
| Trachtenberg Eric |
SEE REMARKS |
• – – |
2023-06-22 |
4 |
A |
$0.00 |
$0 |
D/D |
37,559 |
64,693 |
|
- |
|
| Brazzell Kim |
SEE REMARKS |
• – – |
2023-06-22 |
4 |
A |
$0.00 |
$0 |
D/D |
49,356 |
85,808 |
|
- |
|
| Myers C. Daniel |
|
– • – |
2023-06-22 |
4 |
A |
$0.00 |
$0 |
D/D |
4,884 |
6,524 |
|
- |
|
| Bazemore Todd |
SEE REMARKS |
• – – |
2023-06-22 |
4 |
A |
$0.00 |
$0 |
D/D |
48,698 |
84,691 |
|
- |
|
| Farid Marjan |
|
– • – |
2023-06-22 |
4 |
A |
$0.00 |
$0 |
D/D |
4,792 |
6,392 |
|
- |
|
| Blumenkranz Mark S. |
|
– • – |
2023-06-22 |
4 |
A |
$0.00 |
$0 |
D/D |
4,884 |
11,691 |
|
- |
|
| Rosen Howard B |
|
– • – |
2023-06-22 |
4 |
A |
$0.00 |
$0 |
D/D |
9,088 |
12,487 |
|
- |
|
| Iwicki Mark T |
CHIEF EXECUTIVE OFFICER |
• • – |
2023-06-22 |
4 |
A |
$0.00 |
$0 |
D/D |
158,873 |
276,554 |
|
- |
|
| Bazemore Todd |
SEE REMARKS |
• – – |
2023-05-31 |
4 |
A |
$0.00 |
$0 |
D/D |
21,158 |
35,993 |
|
- |
|
144 Records found
|
|
Page 1 of 6 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.12 (1.94%) 
